

EuroPCR 2026

19 - 22 May 2026 | Paris, France

The Leading Course in Interventional Cardiology

From 19–22 May, colleagues from EMEA, APAC, and LATAM came together in Paris for EuroPCR 2026, one of the world’s leading congresses in interventional cardiovascular medicine. The congress provided a valuable platform to exchange regional perspectives, strengthen cross-functional collaboration, and gain insights into the latest advancements in interventional cardiology, intracoronary imaging, calcium modification, and emerging vascular therapies.



Congress Highlights

OrbusNeich® engaged physicians, distributors, and business partners through booth activities, scientific discussions, and product demonstrations, strengthening brand visibility across EMEA, APAC, and LATAM. The congress also provided valuable opportunities to deepen existing partnerships, explore new distributor collaborations, and gather product feedback, market insights, and competitive intelligence.

The Sapphire® Family showcase attracted strong interest and sparked discussions on lesion preparation strategies, product performance, and real-world clinical applications. In addition, internal IVUS training sessions enhanced colleagues' understanding of IVUS fundamentals and clinical applications in PCI, supporting knowledge sharing and future educational initiatives.

Presentation by Dr. Kuo Feng Yu

On 20 May, Dr. Kuo Feng Yu presented the **three-year clinical outcomes of an ultra-thin strut drug-eluting stent (DES) in complex coronary lesions** at EuroPCR 2026. The retrospective, single-arm study enrolled 413 high-risk, real-world patients to evaluate the safety and efficacy of the ultra-thin stent over 36 months.

The study demonstrated durable long-term safety and efficacy, with low rates of cardiac death and myocardial infarction, and no late revascularisation catch-up through three years. These findings support the use of the ultra-thin strut DES as a reliable treatment option for complex PCI in routine clinical practice.



Overall, EuroPCR 2026 delivered valuable scientific updates, strengthened internal collaboration across EMEA, APAC and LATAM teams, reinforced IVUS educational initiatives, and generated actionable insights to support future clinical education, product training, and regional development activities.